hereditary transthyretin-mediated amyloidosis (ATTRv)

asg-webinar.jpg
Jul 15, 2023
Virtual Meeting – Amyloidosis Support Groups – Saturday, July 15, 2023
Date & Time Saturday, July 15, 2023 12:00 PM ET Description Please join ASG on Saturday, July 15th from 12:00 pm - 3:00 pm ET for the next webinar on ATTRv and…
Read more
AZI.jpeg
Apr 24, 2023
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
CARLSBAD, Calif., April 24, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Incexternal link, opens in a new tab. (Nasdaq: IONSexternal link, opens in a new tab) today…
Read more
Jan 10, 2021
The Patient Journey Toward a Diagnosis of Hereditary Transthyretin (ATTRv) Amyloidosis
Background: Despite emerging treatments for hereditary transthyretin (ATTRv) amyloidosis, the disease is often misdiagnosed, with reported diagnostic delays of up…
Read more
Jul 02, 2019
Inotersen for the Treatment of Adults With Polyneuropathy Caused by Hereditary Transthyretin-Mediated Amyloidosis
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a…
Read more
Nutrition Guidelines for Patients: Hereditary Transthyretin Amyloidosis (Spanish)
Adopting simple, healthy habits is one of the most influential factors in developing a balanced lifestyle. Nutrition affects overall physical and mental health and…
Read more
Subscribe to